SCHEMBL134555

SCHEMBL134555

CC[C@@H](F)C(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL310632 1.00
SCHEMBL30730720 1.00
SCHEMBL323205 1.00
Hydrochloric Acid SCHEMBL7045331 0.97
Hydrochloric Acid SCHEMBL18334389 0.97
SCHEMBL18803450 0.97
Ethane SCHEMBL8667520 0.97
SCHEMBL30302615 0.82 MAPT (0.39)
SCHEMBL28959510 0.78 MAPT (0.40)
SCHEMBL1028090 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230084521-A1 PROPOFOL PRODRUG METHODS AND COMPOSITIONS EPALEX CORPORATION 2023-03-16 US claimed
US-20220105050-A1 PROPOFOL PRODRUG METHODS AND COMPOSITIONS EPALEX CORPORATION 2022-04-07 US claimed
US-20110021809-A1 Method for Purification of Optically Active alpha-Fluorocarboxylic Acid Esters CENTRAL GLASS COMPANY, LIMITED (JP) 2011-01-27 US claimed
US-20250312361-A1 FOSPROPOFOL METHODS AND COMPOSITIONS EPALEX CORP (US) 2025-10-09 US disclosed
US-12377110-B2 Fospropofol methods and compositions EPALEX CORPORATION (US) 2025-08-05 US disclosed
EP-4288062-A1 FOSPROPOFOL METHODS AND COMPOSITIONS Epalex Corporation (US) 2023-12-13 EP disclosed
US-20230277567-A1 FOSPROPOFOL METHODS AND COMPOSITIONS EPALEX CORPORATION 2023-09-07 US disclosed
US-11628178-B2 Fospropofol methods and compositions EPALEX CORPORATION (US) 2023-04-18 US disclosed
US-20230084521-A1 PROPOFOL PRODRUG METHODS AND COMPOSITIONS EPALEX CORPORATION 2023-03-16 US disclosed
US-20220265686-A1 FOSPROPOFOL METHODS AND COMPOSITIONS EPALEX CORPORATION 2022-08-25 US disclosed
WO-2022169520-A1 FOSPROPOFOL METHODS AND COMPOSITIONS EPALEX CORPORATION (US) 2022-08-11 WO disclosed
US-20090048326-A1 Azabicycloheptyl compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2009-02-19 US disclosed
US-20090012074-A1 Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to modulation of the Dopamine D3 receptor ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2009-01-08 US disclosed
US-20080318996-A1 6-Amino(Aza)Indane Compounds Suitable for Treating Disorders that Respond to Modulation of the Dopamine D3 Receptor ABBOTT GMBH & CO.KG A CORPORATION 2008-12-25 US disclosed
WO-2008049531-A1 STEREOSELECTIVE ONE STEP FLUORINATION PROCESS FOR THE PREPARATION OF 2-FLUOROPROPIONATE BAYER CROPSCIENCE AG (DE) 2008-05-02 WO disclosed
US-20080096934-A1 Aminoethylaromatic Compounds Suitable For Treating Disorders That Respond To Modulation Of The Dopamine D3 Receptor ABBOTT GMBH & CO. KG (DE) 2008-04-24 US disclosed
EP-1809598-A1 AMINOMETHYL SUBSTITUTED BICYCLIC AROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR Abbott GmbH & Co. KG (DE) 2007-07-25 EP disclosed
WO-2006040180-A1 AMINOMETHYL SUBSTITUTED BICYCLIC AROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR ABBOTT GMBH & CO. KG (DE) 2006-04-20 WO disclosed
US-20040157739-A1 Amino-1,3,5-triazines N-substituted with chiral bicyclic radicals, process for their preparation, compositions thereof, and their use as herbicides and plant growth regulators BAYER CROPSCIENCE AG (DE) 2004-08-12 US disclosed
US-5244597-A Liquid crystalline mixtures having a chiral tilted smectic phase HOFFMANN-LA ROCHE INC. (US) 1993-09-14 US disclosed